Amphista Therapeutics is the leading European targeted protein degradation (TPD) company.
We have developed several completely novel mechanisms to remove disease-causing proteins with the potential to overcome many of the limitations seen with current TPD approaches. Our therapeutics, known as Amphistas, have the potential to deliver transformational medicines to treat a wide range of diseases.
Latest news
- Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium 23 May 2024
- Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders 24 January 2024
Careers
We are seeking exceptional and visionary scientists, to join our team in this cutting-edge therapeutic modality, bringing hope to those patients with life-changing diseases.